StemoniX Inc. provides IPS-based platforms for pharma and research institutions. The company offers StemoniX, a platform that focuses on printing of stem-cell derived human tissue for custom drug discovery and personalized medicine. Its solution enables scaled 3-D printing of living cells into larger form factors for heart disease, dementia, breast cancer, autism, ALS, and more. The company was incorporated in 2014 and is headquartered in Minneapolis, Minnesota with an additional office in LA Jolla, California. This company has other shares of common stock that are publicly traded. See the "related symbols" tab.
$3.84
As of 04/14/2021 IEX book CBOE book
2021 © Stock Market MBA, Inc.